BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12593042)

  • 1. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 8. [Vigabatrin and visual fields defects].
    Jensen K
    Ugeskr Laeger; 2001 Jan; 163(2):184. PubMed ID: 11379251
    [No Abstract]   [Full Text] [Related]  

  • 9. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
    Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
    Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 11. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 12. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin-associated visual field loss.
    Fecarotta C; Sergott RC
    Int Ophthalmol Clin; 2012; 52(3):87-94, xii. PubMed ID: 22668542
    [No Abstract]   [Full Text] [Related]  

  • 14. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

  • 15. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
    Comaish IF; Gorman C; Galloway NR
    BMJ; 2000 May; 320(7246):1403; author reply 1404. PubMed ID: 10858054
    [No Abstract]   [Full Text] [Related]  

  • 17. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
    Riise P; Fledelius HC; Rogvi-Hansen Bà
    Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epilepsy and Sabril].
    Depasse F
    Bull Soc Belge Ophtalmol; 2007; (304):33-40. PubMed ID: 17718226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.